NO20041141L - Substituerte 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-on og 7-pyridinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)on-derivater - Google Patents
Substituerte 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-on og 7-pyridinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)on-derivaterInfo
- Publication number
- NO20041141L NO20041141L NO20041141A NO20041141A NO20041141L NO 20041141 L NO20041141 L NO 20041141L NO 20041141 A NO20041141 A NO 20041141A NO 20041141 A NO20041141 A NO 20041141A NO 20041141 L NO20041141 L NO 20041141L
- Authority
- NO
- Norway
- Prior art keywords
- group
- ring
- atom
- optionally substituted
- alkyl group
- Prior art date
Links
- YHPVIBUEXBEHPV-UHFFFAOYSA-N 2,6-dihydro-1h-pyrimidin-5-one Chemical class O=C1CNCN=C1 YHPVIBUEXBEHPV-UHFFFAOYSA-N 0.000 title 1
- KTZSHRGZRORXJO-UHFFFAOYSA-N 2-pyridin-2-yl-1,6,7,8-tetrahydropyrimido[1,2-a]pyrimidin-4-one Chemical class N1=C2NCCCN2C(=O)C=C1C1=CC=CC=N1 KTZSHRGZRORXJO-UHFFFAOYSA-N 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 101150053721 Cdk5 gene Proteins 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- SZTLZVPTFVVGML-UHFFFAOYSA-N n-ethenylidenehydroxylamine Chemical group ON=C=C SZTLZVPTFVVGML-UHFFFAOYSA-N 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000008318 pyrimidones Chemical class 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000003375 sulfoxide group Chemical group 0.000 abstract 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pest Control & Pesticides (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
Abstract
Oppfinnelsen vedrører et pyrimidonderivat representert ved formel {I) eller et salt derav hvori X representerer to hydrogenatomer, et svovelatom, et oksygenatom eller en-alkylgruppe og et hydrogenatom; Y representerer en binding, en etenylengruppe, en etynylengruppe, et oJcsygenatom, et svovelatom, en sulfonylgruppe, en sulfoksydgruppe, en karbo-nylgruppe, en hydroksyiminoetylengruppe, en dioksolangruppe, et nitrogenatom som eventuelt er substituert; eller en metylengruppe som eventuelt er substituert; eller en metylengruppe som eventuelt er substituert; RI representerer en 2-,- eller 4-pyridinring som eventuelt er substituert;kan representere en C-g-alkylgruppe som eventuelt er substituert; en C_-cykloalkylgruppe, en C-alkyltiogruppe, en Cj__4-alkoksygruppe, en Cpérhalogenert alkylgruppe, en Chalogenert alkylgruppe, en fenyltiogruppe, en benzylgruppe, en benzenring, en indanring, en 5,6,7,8-tetrahydronaftalen-ring, en naftalenring, en pyridinring, en pyrrolring, en tio-fenring, en furanring eller en imidazolring; R3 og R4 representerer hver uavhengig et hydrogenatom, en C^.g-alkylgruppe, en hydroksygruppe, en Calkoksygruppe eller et halogenatom; R5 representerer et hydrogenatom, en Cx_ 6- alkylgruppe eller et halogenatom; med den betingelse at når R3 og R4 hver representerer et hydrogenatom da er R5 ikke et hydrogenatom. Oppfinnelsen vedrører også et legemiddel som omfatter derivatet eller et salt derav som en aktiv bestanddel som anvendes for forebyggende og/eller terapeutisk behandling av en nevrodegenerativ sykdom forårsaket av abnorm aktivitet avellerog cdk5/p25, slik somlzheimers sykdom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01402432A EP1295885A1 (en) | 2001-09-21 | 2001-09-21 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives |
| EP02290489A EP1340761A1 (en) | 2002-02-28 | 2002-02-28 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
| PCT/EP2002/011128 WO2003027116A2 (en) | 2001-09-21 | 2002-09-19 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20041141L true NO20041141L (no) | 2004-06-21 |
| NO329565B1 NO329565B1 (no) | 2010-11-15 |
Family
ID=26077256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20041141A NO329565B1 (no) | 2001-09-21 | 2004-03-18 | Substituerte 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)on-derivater, anvendelser av slike derivater, og legemidler og inhibitorer omfattende slike derivater |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7214682B2 (no) |
| EP (2) | EP1430057B1 (no) |
| JP (3) | JP4570362B2 (no) |
| KR (1) | KR100868841B1 (no) |
| CN (2) | CN1247585C (no) |
| AR (1) | AR036600A1 (no) |
| AT (2) | ATE401309T1 (no) |
| AU (1) | AU2002350487C1 (no) |
| BR (1) | BR0212896A (no) |
| CA (1) | CA2457965C (no) |
| CY (1) | CY1108341T1 (no) |
| DE (2) | DE60227718D1 (no) |
| DK (2) | DK1430057T3 (no) |
| EA (1) | EA006859B1 (no) |
| ES (2) | ES2247398T3 (no) |
| HU (1) | HUP0500328A3 (no) |
| IL (2) | IL160402A0 (no) |
| MX (1) | MXPA04002629A (no) |
| NO (1) | NO329565B1 (no) |
| NZ (2) | NZ531243A (no) |
| PL (1) | PL370349A1 (no) |
| PT (1) | PT1674456E (no) |
| SI (1) | SI1430057T1 (no) |
| WO (1) | WO2003027116A2 (no) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ531243A (en) * | 2001-09-21 | 2006-08-31 | Sanofi Aventis | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)one derivatives |
| TW201041580A (en) | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| EP1454909B1 (en) * | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro- (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one derivatives and their use against neurodegenerative diseases |
| EP1454900A1 (en) * | 2003-03-07 | 2004-09-08 | Sanofi-Synthelabo | Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters |
| EP1557417B1 (en) * | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
| WO2005070932A2 (en) | 2004-01-22 | 2005-08-04 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CN101735211B (zh) * | 2008-11-04 | 2012-11-14 | 复旦大学 | 2,3-二氢[1,5]苯并噻氮杂*类化合物或其盐在制备GSK-3β抑制剂中的用途 |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| FR2947550B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
| HUE034503T2 (en) | 2009-07-02 | 2018-02-28 | Sanofi Sa | 2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine |
| ES2487623T3 (es) * | 2009-07-02 | 2014-08-22 | Sanofi | Derivados de 6,7,8,9-tetrahidro-pirimido{1,2-a}pirimidin-4-ona, su preparación y su aplicación farmacéutica |
| FR2947551B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
| HUE024504T2 (en) | 2010-12-23 | 2016-01-28 | Sanofi Sa | Pyrimidine derivatives, a process for their preparation and their use in medicine |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| CN109836427B (zh) * | 2017-11-29 | 2022-04-15 | 暨南大学 | 嘧啶并嘧啶酮类化合物及其应用 |
| CN114957246B (zh) * | 2021-02-19 | 2025-11-11 | 苏州恩华生物医药科技有限公司 | 5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4（3H）-酮衍生物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998016528A1 (en) | 1996-10-11 | 1998-04-23 | Chiron Corporation | Purine inhibitors of glycogen synthase kinase 3 (gsk3) |
| BR9713863A (pt) | 1996-12-05 | 2000-03-14 | Amgen Inc | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase |
| CN1312807A (zh) | 1998-06-19 | 2001-09-12 | 希龙公司 | 糖元合成酶激酶3的抑制剂 |
| AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| JP2000264888A (ja) * | 1999-01-11 | 2000-09-26 | Sagami Chem Res Center | 双環性ピリミジン誘導体、それらの製造中間体及びそれらの製造方法、並びにそれらを有効成分とする除草剤 |
| UA67832C2 (uk) * | 1999-03-22 | 2004-07-15 | Орто-Макнейл Фармацевтикал, Інк. | СПОСІБ ОТРИМАННЯ [S-(R<sup>*</sup>,S<sup>*</sup>)]-<font face="Symbol">b</font>-[[[1-[1-ОКСО-3-(4-ПІПЕРИДИНІЛ)ПРОПІЛ]-3-ПІПЕРИДИНІЛ]КАРБОНІЛ]АМІНО]-3-ПІРИДИНПРОПАНОВОЇ КИСЛОТИ ТА ЇЇ ПОХІДНИХ |
| WO2001042224A1 (en) * | 1999-12-09 | 2001-06-14 | Mitsubishi Pharma Corporation | Carboxyamido derivatives |
| EP1240168B1 (en) | 1999-12-17 | 2005-08-31 | Chiron Corporation | Bicyclic inhibitors of glycogen synthase kinase 3 |
| CN100339379C (zh) * | 2000-09-01 | 2007-09-26 | 圣诺菲-合成实验室公司 | 2－吡啶基－6,7,8,9－四氢嘧啶并[1,2－а]嘧啶－4－酮和7－吡啶基－2,3－二氢咪唑并[1,2－а]嘧啶－5（1H）酮衍生物 |
| NZ531243A (en) * | 2001-09-21 | 2006-08-31 | Sanofi Aventis | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)one derivatives |
-
2002
- 2002-09-19 NZ NZ531243A patent/NZ531243A/en not_active IP Right Cessation
- 2002-09-19 NZ NZ547205A patent/NZ547205A/en not_active IP Right Cessation
- 2002-09-19 CA CA2457965A patent/CA2457965C/en not_active Expired - Fee Related
- 2002-09-19 AT AT05016160T patent/ATE401309T1/de active
- 2002-09-19 DK DK02785157T patent/DK1430057T3/da active
- 2002-09-19 KR KR1020047004139A patent/KR100868841B1/ko not_active Expired - Fee Related
- 2002-09-19 EP EP02785157A patent/EP1430057B1/en not_active Expired - Lifetime
- 2002-09-19 HU HU0500328A patent/HUP0500328A3/hu unknown
- 2002-09-19 ES ES02785157T patent/ES2247398T3/es not_active Expired - Lifetime
- 2002-09-19 IL IL16040202A patent/IL160402A0/xx active IP Right Grant
- 2002-09-19 SI SI200230201T patent/SI1430057T1/sl unknown
- 2002-09-19 PT PT05016160T patent/PT1674456E/pt unknown
- 2002-09-19 BR BR0212896-9A patent/BR0212896A/pt not_active Application Discontinuation
- 2002-09-19 JP JP2003530704A patent/JP4570362B2/ja not_active Expired - Fee Related
- 2002-09-19 EA EA200400237A patent/EA006859B1/ru not_active IP Right Cessation
- 2002-09-19 US US10/490,135 patent/US7214682B2/en not_active Expired - Fee Related
- 2002-09-19 AU AU2002350487A patent/AU2002350487C1/en not_active Ceased
- 2002-09-19 CN CNB02818338XA patent/CN1247585C/zh not_active Expired - Fee Related
- 2002-09-19 AT AT02785157T patent/ATE303388T1/de active
- 2002-09-19 DE DE60227718T patent/DE60227718D1/de not_active Expired - Lifetime
- 2002-09-19 DK DK05016160T patent/DK1674456T3/da active
- 2002-09-19 ES ES05016160T patent/ES2310787T3/es not_active Expired - Lifetime
- 2002-09-19 PL PL02370349A patent/PL370349A1/xx unknown
- 2002-09-19 WO PCT/EP2002/011128 patent/WO2003027116A2/en not_active Ceased
- 2002-09-19 MX MXPA04002629A patent/MXPA04002629A/es active IP Right Grant
- 2002-09-19 DE DE60205921T patent/DE60205921T2/de not_active Expired - Lifetime
- 2002-09-19 EP EP05016160A patent/EP1674456B1/en not_active Expired - Lifetime
- 2002-09-19 CN CNB2006100043835A patent/CN100398541C/zh not_active Expired - Fee Related
- 2002-09-20 AR ARP020103541A patent/AR036600A1/es unknown
-
2004
- 2004-02-15 IL IL160402A patent/IL160402A/en not_active IP Right Cessation
- 2004-03-18 NO NO20041141A patent/NO329565B1/no not_active IP Right Cessation
-
2007
- 2007-04-05 US US11/696,982 patent/US7462621B2/en not_active Expired - Fee Related
-
2008
- 2008-09-16 CY CY20081100994T patent/CY1108341T1/el unknown
-
2010
- 2010-04-22 JP JP2010098977A patent/JP2010159303A/ja active Pending
- 2010-04-22 JP JP2010098978A patent/JP2010209089A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20041141L (no) | Substituerte 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-on og 7-pyridinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)on-derivater | |
| EA200600196A1 (ru) | Производные замещенного 2-пиримидинил-6,7,8,9-тетрагидропиримидо[1,2-a]пиримидин-4-она и 7-пиримидинил-2,3-дигидроимидазо[1,2-a]пиримидин-5(1н) она для нейродегенеративных нарушений | |
| NO20020811L (no) | Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler | |
| NO20054331L (no) | Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater | |
| TW200510418A (en) | Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido [1, 2-a] pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido [1, 2-a] pyrimidin-6-one derivatives | |
| NO20054330L (no) | 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater | |
| NO20063187L (no) | Substituerte 8'-pyri(mi)dinyl-dihydrospiro-[cykloalkylamin]-pyrimido[1,2-a]pyrimidin-6-on-derivater | |
| AR030587A1 (es) | Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)-ona | |
| EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
| BR0308109A (pt) | Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila | |
| WO2008056266A8 (en) | Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a]pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a]pyrimidin-6-one derivatives | |
| ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| DE69727915D1 (de) | Substituierte vinylpyridinderivate und arzneimittel, die diese enthalten | |
| BR0215222A (pt) | Derivados de indolilalquilamina como ligantes de 5-hidroxitriptamina-6 | |
| DE69635857D1 (de) | Pyrrolderivate und medizinische zubereitung. | |
| ATE242246T1 (de) | (1,2,3)-triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel | |
| BR0308106A (pt) | Derivados de 1-[alquil], 1[(heteroaril)alquil] e 1-[(aril)alquil]-7-(pirimidin-4-il)-imidazo[1,2-a]pirimidin-5- (1h)-ona | |
| EA200801134A1 (ru) | Замещенные бициклические пиримидоновые производные | |
| EA200300150A1 (ru) | ПРОИЗВОДНЫЕ 1-[АЛКИЛ], 1-[(ГЕТЕРОАРИЛ)АЛКИЛ] И 1-[(АРИЛ)АЛКИЛ]-7-ПИРИДИНИЛ-ИМИДАЗО[1, 2-a]ПИРИМИДИН-5(1H)ОНА | |
| EA200501243A1 (ru) | Замещенные производные 2-(диазабициклоалкил)пиримидона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |